Literature DB >> 23887834

Relationship between onset-to-door time and door-to-thrombolysis time: a pooled analysis of 10 dedicated stroke centers.

Daniel Strbian1, Patrik Michel, Peter Ringleb, Heikki Numminen, Lorenz Breuer, Marie Bodenant, David J Seiffge, Simon Jung, Victor Obach, Bruno Weder, Marjaana Tiainen, Ashraf Eskandari, Christoph Gumbinger, Henrik Gensicke, Angel Chamorro, Heinrich P Mattle, Stefan T Engelter, Didier Leys, Martin Köhrmann, Anna-Kaisa Parkkila, Werner Hacke, Turgut Tatlisumak.   

Abstract

BACKGROUND AND
PURPOSE: Inverse relationship between onset-to-door time (ODT) and door-to-needle time (DNT) in stroke thrombolysis was reported from various registries. We analyzed this relationship and other determinants of DNT in dedicated stroke centers.
METHODS: Prospectively collected data of consecutive ischemic stroke patients from 10 centers who received IV thrombolysis within 4.5 hours from symptom onset were merged (n=7106). DNT was analyzed as a function of demographic and prehospital variables using regression analyses, and change over time was considered.
RESULTS: In 6348 eligible patients with known treatment delays, median DNT was 42 minutes and kept decreasing steeply every year (P<0.001). Median DNT of 55 minutes was observed in patients with ODT ≤30 minutes, whereas it declined for patients presenting within the last 30 minutes of the 3-hour time window (median, 33 minutes) and of the 4.5-hour time window (20 minutes). For ODT within the first 30 minutes of the extended time window (181-210 minutes), DNT increased to 42 minutes. DNT was stable for ODT for 30 to 150 minutes (40-45 minutes). We found a weak inverse overall correlation between ODT and DNT (R(2)=-0.12; P<0.001), but it was strong in patients treated between 3 and 4.5 hours (R(2)=-0.75; P<0.001). ODT was independently inversely associated with DNT (P<0.001) in regression analysis. Octogenarians and women tended to have longer DNT.
CONCLUSIONS: DNT was decreasing steeply over the last years in dedicated stroke centers; however, significant oscillations of in-hospital treatment delays occurred at both ends of the time window. This suggests that further improvements can be achieved, particularly in the elderly.

Entities:  

Keywords:  door-to-needle time; emergencies; ischemic stroke; outcome; thrombolysis

Mesh:

Year:  2013        PMID: 23887834     DOI: 10.1161/STROKEAHA.113.000995

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  17 in total

1.  Predictors of diagnostic neuroimaging delays among adults presenting with symptoms suggestive of acute stroke in Ontario: a prospective cohort study.

Authors:  Kirsteen R Burton; Moira K Kapral; Shudong Li; Jiming Fang; Alan R Moody; Murray Krahn; Andreas Laupacis
Journal:  CMAJ Open       Date:  2016-06-20

2.  Intravenous thrombolysis for ischemic stroke in the golden hour: propensity-matched analysis from the SITS-EAST registry.

Authors:  Georgios Tsivgoulis; Aristeidis H Katsanos; Pavla Kadlecová; Anna Czlonkowska; Adam Kobayashi; Miroslav Brozman; Viktor Švigelj; Laszlo Csiba; Klara Fekete; Janika Kõrv; Vida Demarin; Aleksandras Vilionskis; Dalius Jatuzis; Yakup Krespi; Chrissoula Liantinioti; Sotirios Giannopoulos; Robert Mikulik
Journal:  J Neurol       Date:  2017-03-18       Impact factor: 4.849

3.  A Decade of Improvement in Door-to-Needle Time Among Acute Ischemic Stroke Patients, 2008 to 2017.

Authors:  Xin Tong; Jennifer L Wiltz; Mary G George; Erika C Odom; Sallyann M Coleman King; Tiffany Chang; Xiaoping Yin; Robert K Merritt
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-12

4.  Stroke 20 20: Implementation goals for intravenous thrombolysis.

Authors:  Robert Mikulik; Michal Bar; David Cernik; Roman Herzig; Rene Jura; Lubomir Jurak; Jiri Neumann; Daniel Sanak; Svatopluk Ostry; Petr Sevcik; Ondrej Skoda; David Skoloudik; Daniel Vaclavik; Ales Tomek
Journal:  Eur Stroke J       Date:  2021-04-12

5.  Ultrashort Door-to-Needle Time for Intravenous Thrombolysis Is Safer and Improves Outcome in the Czech Republic: Nationwide Study 2004 to 2019.

Authors:  Robert Mikulík; Michal Bar; Silvie Bělašková; David Černík; Jan Fiksa; Roman Herzig; René Jura; Lubomír Jurák; Lukáš Klečka; Jiří Neumann; Svatopluk Ostrý; Daniel Šaňák; Petr Ševčík; Ondřej Škoda; Martin Šrámek; Aleš Tomek; Daniel Václavík
Journal:  J Am Heart Assoc       Date:  2022-05-16       Impact factor: 6.106

6.  The SITS-UTMOST: A registry-based prospective study in Europe investigating the impact of regulatory approval of intravenous Actilyse in the extended time window (3-4.5 h) in acute ischaemic stroke.

Authors:  Niaz Ahmed; Karin Hermansson; Erich Bluhmki; Thierry Danays; Ana Paiva Nunes; Anthony Kenton; Sekaran Lakshmanan; Danilo Toni; Robert Mikulik; Gary A Ford; Kennedy R Lees; Nils Wahlgren
Journal:  Eur Stroke J       Date:  2016-07-29

7.  Process improvement to enhance existing stroke team activity toward more timely thrombolytic treatment.

Authors:  Han-Jin Cho; Kyung Yul Lee; Hyo Suk Nam; Young Dae Kim; Tae-Jin Song; Yo Han Jung; Hye-Yeon Choi; Ji Hoe Heo
Journal:  J Clin Neurol       Date:  2014-10-06       Impact factor: 3.077

Review 8.  How can we improve stroke thrombolysis rates? A review of health system factors and approaches associated with thrombolysis administration rates in acute stroke care.

Authors:  Christine L Paul; Annika Ryan; Shiho Rose; John R Attia; Erin Kerr; Claudia Koller; Christopher R Levi
Journal:  Implement Sci       Date:  2016-04-08       Impact factor: 7.327

Review 9.  If Time Is Brain Where Is the Improvement in Prehospital Time after Stroke?

Authors:  Jeremy N Pulvers; John D G Watson
Journal:  Front Neurol       Date:  2017-11-20       Impact factor: 4.003

10.  Prehospital and intra-hospital time delays in posterior circulation stroke: results from the Austrian Stroke Unit Registry.

Authors:  Peter Sommer; Leonhard Seyfang; Alexandra Posekany; Julia Ferrari; Wilfried Lang; Elisabeth Fertl; Wolfgang Serles; Thomas Töll; Stefan Kiechl; Stefan Greisenegger
Journal:  J Neurol       Date:  2016-11-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.